This category covers biotechnology and pharmaceutical companies developing therapies targeting ferroptosis — an iron-dependent form of regulated cell death characterized by lipid peroxidation accumulation — for the treatment of Alzheimer's disease. Ferroptosis is increasingly recognized as a key mechanism contributing to neuronal loss in AD, with evidence pointing to impaired glutathione peroxidase 4 (GPX4) function, iron dyshomeostasis, and lipid peroxidation accumulation in affected brain regions.
Unlike apoptosis or necrosis, ferroptosis is distinctively characterized by:
- Iron-dependent accumulation of lipid peroxides
- Loss of GPX4 activity leading to membrane lipid damage
- Sensitivity to iron chelation and lipid antioxidant treatment
- Distinct morphological features (smaller mitochondria, dense membrane)
Companies in this space pursue several mechanisms targeting different nodes of the ferroptosis pathway, including iron chelation, GPX4 activation/inhibition prevention, lipid peroxidation scavenging, and coenzyme Q10 redox augmentation.
Reducing labile iron availability that drives Fenton reactions and lipid peroxide formation. Deferiprone and similar BBB-penetrant chelators.
Restoring or enhancing GPX4 function to reduce lipid peroxides. Includes direct GPX4 modulators and upregulation strategies.
Scavenging lipid peroxyl radicals before they damage membranes. Ferrostatin-1 analogs and lipophilic antioxidants.
FSP1-mediated CoQ10 reduction provides alternative lipid peroxidation defense independent of GPX4.
- Focus: Glutaminyl cyclase inhibition with secondary ferroptosis modulation
- Lead Candidate: Varoglutamstat (PQ912)
- Indication: Early Alzheimer's disease
- Stage: Phase IIb (VIVIAD trial)
- Mechanism: Inhibits glutaminyl cyclase to reduce pGlu-modified Aβ which exhibits enhanced metal-binding properties; iron homeostasis modulation as secondary mechanism
- Notes: Unique dual mechanism targeting both Aβ pathology and ferroptosis-linked iron dysregulation; demonstrated target engagement in Phase IIa SAPIR trial
- Related Page: Vivoryon Therapeutics
- Focus: Iron chelation therapy
- Lead Candidate: Deferiprone
- Indication: Alzheimer's disease (exploratory)
- Stage: Research/Preclinical
- Mechanism: Oral iron chelator that crosses the blood-brain barrier and reduces brain iron stores implicated in ferroptosis
- Notes: Primarily focused on Parkinson's disease (FAIRPARK trials); investigating applicability to AD where iron accumulation occurs in regions like the basal ganglia
- Related Page: Apopharma Inc.
- Focus: GPX4-targeted small molecules
- Lead Candidates: FRX-101, FRX-201 (research compounds)
- Indication: Alzheimer's disease / ALS
- Stage: Discovery/Preclinical
- Mechanism: Direct GPX4 activity modulators designed to prevent ferroptotic cell death
- Notes: Academic-industry collaboration focused on ferroptosis modulation; working on BBB-penetrant analogs of known GPX4 modulators
- Focus: Lipid peroxidation inhibitors
- Lead Candidate: LRN-001
- Indication: Alzheimer's disease
- Stage: Discovery
- Mechanism: Novel small molecule lipid peroxyl radical scavengers
- Notes: Development-stage company targeting ferroptosis modulators for neurodegenerative diseases
- Focus: Basic research on ferroptosis mechanisms in neurodegeneration
- Key Researchers: Dr. [Researcher Name], Dr. [Researcher Name]
- Mechanism Areas: GPX4 biology, iron metabolism, lipid peroxidation
- Notes: Academic research consortium providing mechanistic foundations for ferroptosis-targeted drug development; collaborates with industry on compound screening
- Focus: Iron dyshomeostasis and ferroptosis in AD
- Key Researchers: Dr. [Researcher Name]
- Mechanism Areas: Brain iron metabolism, transferrin dynamics
- Notes: Leading academic center for iron biology in neurodegeneration; developing biomarkers for ferroptosis
- Focus: Mitochondria-targeted antioxidants
- Lead Candidate: MT-101
- Mechanism: CoQ10 redox augmentation targeting mitochondrial ferroptosis defense
- Notes: Works through FSP1/CoQ10 pathway which provides GPX4-independent lipid peroxidation defense
- Related Page: MitoThera
- Focus: Nanocrystalline cleans for neurodegenerative diseases
- Lead Candidate: CNM-Au8
- Mechanism: Redox-active gold nanocrycles that support antioxidant pathways including those relevant to ferroptosis
- Stage: Phase 2
- Related Page: Clene Nanomedicine
| Company |
Drug |
Mechanism |
Indication |
Stage |
| Vivoryon Therapeutics |
Varoglutamstat |
QC inhibition + iron modulation |
Early AD |
Phase IIb |
| Apopharma |
Deferiprone |
Iron chelation |
AD (exploratory) |
Preclinical |
| Ferro Rx |
FRX-101 |
GPX4 modulation |
AD/ALS |
Discovery |
| MitoThera |
MT-101 |
CoQ10 augmentation |
Neurodegeneration |
Preclinical |
| Clene Nanomedicine |
CNM-Au8 |
Nanocrystal redox |
ALS |
Phase 2 |